The personalised healthcare subsidiary of NantWorks, backed by Celgene, Blackberry and Allscripts, has priced its initial public offering at $14 a share.

The Naver-owned messaging platform, which first hoped to float in 2014 but dropped the plans in mid-215, is now aiming for a valuation of up to $3bn.

The biopharmaceutical company, which has raised about $480m in equity funding from backers including Novo and AbbVie, has floated on Nasdaq.

The immuno-oncology drug developer, backed by several pharmaceutical firms, has raised $55m in an IPO that saw it float substantially below its $14 to $16 range.

The sports marketing platform is planning to float in China, providing an exit to shareholders including sporting apparel producer Guirenniao.

The biosimilar developer, backed by Strides Arcolab, floated at around half the price of its range having first filed for a $115m initial public offering in January 2016.

The gene editing company raised $108m in its IPO, floating at the top of its range, while Regeneron and Novartis provided $55m through concurrent private placements.

HNA Tourism and Legend-backed holiday home rental portal Zhubaijia has listed on China's Neeq exchange.

The app-based home cleaning service has floated on the National Equities Exchange and Quotations market after raising four rounds of funding from investors including Tencent and Shanda.

Aeglea Biotherapeutics, which is developing amino acid-targeted cancer and metabolic disease treatments, had raised $53.5m in VC funding from investors including Novartis and Eli Lilly.